Johnson & Johnson (JNJ)

NYSE: JNJ · IEX Real-Time Price · USD
147.52
-1.27 (-0.85%)
At close: Apr 12, 2024, 4:00 PM
148.00
+0.48 (0.33%)
Pre-market: Apr 15, 2024, 4:42 AM EDT
-0.85%
Market Cap 355.34B
Revenue (ttm) 85.16B
Net Income (ttm) 35.15B
Shares Out 2.41B
EPS (ttm) 13.72
PE Ratio 10.75
Forward PE 13.72
Dividend $4.76 (3.23%)
Ex-Dividend Date Feb 16, 2024
Volume 7,003,536
Open 148.06
Previous Close 148.79
Day's Range 147.15 - 149.07
52-Week Range 144.95 - 175.97
Beta 0.53
Analysts Buy
Price Target 166.92 (+13.15%)
Earnings Date Apr 16, 2024

About JNJ

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]

Sector Healthcare
IPO Date Sep 24, 1944
Employees 131,900
Stock Exchange NYSE
Ticker Symbol JNJ
Full Company Profile

Financial Performance

In 2023, JNJ's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $166.92, which is an increase of 13.15% from the latest price.

Price Target
$166.92
(13.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity

South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol.

1 day ago - Reuters

Earnings setup: UnitedHealth, Johnson & Johnson, Genuine Parts, P&G, Taiwan Semi & American Express

The Investment Committee give you their earnings setup for next week.

Other symbols: AXPGPCPGTSMUNH
2 days ago - CNBC Television

Kenya recalls J&J children's cough syrup over suspected toxicity

Kenya's drug regulator is recalling a batch of Johnson & Johnson children's cough syrup, it said on Thursday, a day after Nigeria recalled the same batch of medication under the Benylin Paediatric bra...

3 days ago - Reuters

Nigeria recalls J&J children's cough syrup over toxic substance

Nigeria's health regulator is recalling a batch of Johnson & Johnson children's cough syrup after finding an unacceptably high level of a potentially fatal toxic substance, it said on Wednesday.

4 days ago - Reuters

What's Next For Johnson & Johnson Stock After A 6% Decline In A Month?

Johnson & Johnson (NYSE: JNJ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market.

4 days ago - Forbes

Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival

J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.

5 days ago - CNBC

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medica...

Other symbols: SWAV
6 days ago - Business Wire

Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barcla...

6 days ago - Business Wire

Is Johnson & Johnson Stock A Better Pick Over AbbVie?

We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing rev...

Other symbols: ABBV
6 days ago - Forbes

U.S. FDA approves expanded use of J&J's cancer cell therapy

The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cance...

9 days ago - Reuters

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from...

9 days ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.

NEW YORK, April 5, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Shockwave Medical, Inc. (NASDAQ: SWAV) and its board of directors concerning the propose...

Other symbols: SWAV
9 days ago - PRNewsWire

J&J Acquires Shockwave Medical to Boost Its Cardiovascular Treatment Portfolio

Johnson & Johnson (JNJ) announced Friday it was buying Shockwave Medical (SWAV) for $13.1 billion in cash, pushing shares of the maker of cardiovascular catheters to near all-time highs.

Other symbols: SWAV
9 days ago - Investopedia

Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal

The healthcare giant said the addition of the medical-device maker would expand its MedTech cardiovascular portfolio.

Other symbols: SWAV
9 days ago - WSJ

Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal

Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as ...

Other symbols: SWAV
9 days ago - Forbes

Johnson & Johnson to buy Shockwave Medical for $12.5 billion

Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium ...

Other symbols: SWAV
9 days ago - Invezz

Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.

Johnson & Johnson is buying the medical-devices maker for a total enterprise value of about $13.1 billion.

Other symbols: SWAV
9 days ago - Barrons

Johnson & Johnson to acquire Shockwave Medical in $13.1 billion deal

Johnson & Johnson JNJ, -1.14% has agreed to acquire Shockwave Medical Inc. SWAV, -0.23% in an all-cash deal with an enterprise value of about $13 billion, the companies said Friday. J&J will pay $335 ...

Other symbols: SWAV
9 days ago - Market Watch

Johnson & Johnson to buy Shockwave Medical for $12.5 bln

Johnson & Johnson will buy medical device maker Shockwave Medical for about $12.5 billion, the companies said on Friday, helping the healthcare conglomerate boost its portfolio of medical devices.

Other symbols: SWAV
9 days ago - Reuters

Johnson & Johnson to Acquire Shockwave Medical

NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definit...

Other symbols: SWAV
9 days ago - Business Wire

Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Ca...

10 days ago - Business Wire

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.

Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.

Other symbols: BMYMRKPFE
11 days ago - Barrons

Johnson & Johnson Expands Commitment to Advance Health Equity

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson announced today that it is collaborating with more than 100 community-led health organizations supporting historically marginalized communities ...

11 days ago - Business Wire

Johnson & Johnson to Participate in the BofA Securities Health Care Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada. John Re...

12 days ago - Business Wire

Final Trades: JNJ, M, IYH & CLF

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: CLFIYHM
18 days ago - CNBC Television